Not such a small diagnosis: small cell carcinoma of the prostate

Rauf, Abdul; Smith, Stephanie F; Mukherjee, Rono; Nasir, Nyla

doi:10.1093/jscr/rjaa117

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study adds to the existing case reports and cohort studies that have reported on outcomes from other parts of the world 1,13,14 . For example, Horne et al presented on 800 patients with SCPC from the National Cancer Database, US, diagnosed between 2004 and 2015 15 .…”

Section: Discussionmentioning

confidence: 85%

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate

Adams²,

McMillan³

et al. 2022

CUAJ

View full text Add to dashboard Cite

Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review of metastatic or unresectable SCPC patients at British Columbia (BC) Cancer centers, studying diagnosis and treatment patterns. Methods: Drug dispensing records from the six BC Cancer centers were obtained from 2002–2017. For each patient, information was collected on baseline information prior to therapy, and for each line of treatment. Treatments at each line were compared regarding time to progression and overall survival by Kaplan-Meier curves. Results: Forty-one patients received treatment; 65.6% had metastatic disease and 61% had pure small cell carcinoma. Median time from treatment to death was 10 months (95% confidence interval [CI] 6–16). Patients with initially prostate-confined disease had a better median overall survival (mOS) of 21 months (95% CI 13–34) compared to those with initially locally advanced (mOS 19 months, 95% CI 5–37) and metastatic disease (mOS 8 months, 95% CI 6–10) (log-rank p=0.0364). All patients received either cisplatin- or carboplatin-based combination chemotherapy as the first-line treatment and 36.7% received second-line therapy. Time to second-line therapy was eight months for those who presented with metastatic SCPC, compared to 13 months for those with initial non-metastatic SCPC. Conclusions: This single-province, multi-institution cohort reports data on unresectable and metastatic SCPC and highlights the poor prognosis of this rare disease entity.

show abstract

Section: Discussionmentioning

confidence: 85%

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate

Adams²,

McMillan³

et al. 2022

CUAJ

View full text Add to dashboard Cite

show abstract

“…First-line regimens involve cytotoxic chemotherapy with a platinum agent, including combinations such as cisplatin and etoposide, carboplatin and etoposide, carboplatin and docetaxel, and carboplatin and cabazitaxel [ 2 ]. As prostate cancer that has progressed to small cell carcinoma lacks AR, there is typically no place in therapy for ADT unless patients are presenting de novo, and the biopsy has a large acinar adenocarcinoma component [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, there exists a rare and highly aggressive subtype known as small cell carcinoma of the prostate (SCCP). This subtype is considered to be a rare and aggressive form of cancer and accounts for less than 2% of all prostate cancers [ 1 ]. This variant of prostate cancer is marked by its distinctive features, including high-grade malignancy, neuroendocrine differentiation, and a unique clinical presentation [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

“…This subtype is considered to be a rare and aggressive form of cancer and accounts for less than 2% of all prostate cancers [ 1 ]. This variant of prostate cancer is marked by its distinctive features, including high-grade malignancy, neuroendocrine differentiation, and a unique clinical presentation [ 1 ]. Despite the severity of this disease, studies in the treatment for this specific disease are lacking and are extrapolated from the data available for the treatment of small cell carcinoma of the lung.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Localized Neuroendocrine Transformation of Prostate Adenocarcinoma: A Case Report and Literature Review of Current Treatment Modalities

Eckrich,

Colon,

Davenport

et al. 2024

Cureus

View full text Add to dashboard Cite

Most prostate cancers are adenocarcinomas. However, there is a rare and aggressive subtype known as small cell carcinoma of the prostate (SCCP). This variant of prostate cancer is marked by its distinctive features, including high-grade malignancy, neuroendocrine differentiation, and a unique clinical presentation, often involving metastases. This report details the presentation and management of a 66-year-old African-American male who was originally diagnosed with high-risk adenocarcinoma of the prostate. At initial diagnosis, the patient was suboptimally treated with radiation alone without androgen deprivation therapy (ADT). On re-biopsy several years later, he was found to have localized recurrent disease with transformation into SCCP. The prognosis for SCCP is poor with a mean survival. Patients typically present with metastases, commonly to the brain, liver, bones, or bladder. SCCP after treatment for adenocarcinoma of the prostate is more common than de novo presentation. The amount of neuroendocrine differentiation of SCCP often increases with treatment, particularly after treatment with ADT. This report emphasizes the importance of timely and optimal care when treating prostate cancer and suggests potential consequences that inappropriate treatment or treatment delays may entail.

show abstract

The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate

Meyer,

Sunkara,

Rothmann

et al. 2024

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Not such a small diagnosis: small cell carcinoma of the prostate

Cited by 3 publications

References 9 publications

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate

The Localized Neuroendocrine Transformation of Prostate Adenocarcinoma: A Case Report and Literature Review of Current Treatment Modalities

The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate

Contact Info

Product

Resources

About